Dose intensity for breast cancer

ONCOLOGY

Volumn 15, Issue 6, 2001, Pages 701-712

  Armstrong, Deborah K ^a   Davidson, Nancy E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BONE MARROW TRANSPLANTATION; BREAST TUMOR; DOSE RESPONSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 0035379860     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J Clin 50:7-33, 2000.
2. Wingo PA, Reies LAG, Roserberg HM, et al: Cancer incidence and mortality, 1972-1995: A report card for the United States. Cancer 82:1197-1207, 1998.
3. Mettlin C: Global Breast cancer mortality statistics. CA Cancer J Clin 49:138-144, 1999.
4. Schabel FM Jr, Griswold DP, Corbett TH, et al: Increasing the therapeutic response rate to anticancer drugs by applying the basic principles of pharmacology. Cancer 50:1160-1167, 1984.
5. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, 1981.
6. Hryniuk W, Bush H: The importance of dose-intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984.
7. Hryniuk W, Levine MN: Analysis of dose-intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 19:1162-1170, 1986.
8. Biganzoli L, Piccart MJ: The bigger the better?... Or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer. Ann Oncol 8:1177-1182, 1997.
9. Tannock IF, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6: 1377-1387, 1988.
10. Engelsman E, Klijn JCM, Rubens RD, et al: "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. Eur J Cancer 27:966-970, 1991.
11. Habeshaw T, Paul R, Jones R, et al: Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: The results of a randomized trial. J Clin Oncol 9:295-304, 1991.
12. French Epirubicin Study Group: A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 2:305-312, 1991.
13. Focan C, Andrien JM, Closon MT, et al: Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 11:1253-1263, 1993.
14. Marschner N, Kreienberg R, Souchon R, et al: Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophos-phamide in metastatic breast cancer: Interim analysis of a prospective randomized trial. Semin Oncol 21(suppl 1):10-16, 1994.
15. Bastholt L, Dalmark M, Gjedde SB, et al: Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14:1146-1155, 1996.
16. 2) in the FEC regimen significantly increases response rate. An international randomized phase III study in metastatic breast cancer. Ann Oncol 8:155-162, 1997.
17. Fountzilas G, Athanassiades A, Giannakkais T, et al: A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Ann Oncol 8:1213-1220, 1997.
18. French Epirubicin Study Group: Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose-intensity and duration of treatment. J Clin Oncol 18:3115-3124, 2000.
19. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996.
20. Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - Results from CALGB 9342 (abstract). Proc Am Soc Clin Oncol 17:101a, 1998.